TY - JOUR
T1 - Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis
AU - Ahmad, Zahoor
AU - Minkowski, Austin
AU - Peloquin, Charles A.
AU - Williams, Kathy N.
AU - Mdluli, Khisimuzi E.
AU - Grosset, Jacques H.
AU - Nuermberger, Eric L.
PY - 2011/4
Y1 - 2011/4
N2 - DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.
AB - DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.
UR - http://www.scopus.com/inward/record.url?scp=79953176996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953176996&partnerID=8YFLogxK
U2 - 10.1128/AAC.01514-10
DO - 10.1128/AAC.01514-10
M3 - Article
C2 - 21282421
AN - SCOPUS:79953176996
SN - 0066-4804
VL - 55
SP - 1781
EP - 1783
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 4
ER -